{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-106030","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2023-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.640296+00:00","generated_at":"2026-06-10T05:31:05.362120+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Hepion Pharmaceuticals raises $5.0M in registered direct offering with warrants","bullets":["Gross proceeds $5.0M from sale of 980,393 shares (or equivalents) at $5.10/share plus warrants.","Series A and B warrants to buy up to 980,393 shares each at $4.85; Series A expires in 5 yrs, Series B in 1.5 yrs.","Closing expected on or about Oct 3, 2023; A.G.P./Alliance Global Partners as placement agent.","Net proceeds intended for clinical development and working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-106030","json":"https://secwatch.observer/filing/0001104659-23-106030.json","markdown":"https://secwatch.observer/filing/0001104659-23-106030.md","text":"https://secwatch.observer/filing/0001104659-23-106030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923106030/0001104659-23-106030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923106030/tm2327415d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T05:31:05.362120+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ac947ca6eac47b5460eacfccc2cd20ef6777d67b","claim":"Hepion Pharmaceuticals, Inc. entered into Purchase Agreement with an institutional investor valued at approximately $5.0 million (effective 2023-09-28).","evidence_excerpt":"On September 28, 2023, Hepion Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor, pursuant to which the Company agreed to issue and sell to such investor, in a registered direct offering (i) 400,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a purchase price of $5.10 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 580,393 shares of the Company’s Common Stock at an exercise price of $0.0001 per share at an offering price of $5.09 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923106030/0001104659-23-106030-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an institutional investor"},{"label":"Value","value":"approximately $5.0 million"},{"label":"Effective","value":"2023-09-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}